Chad Messer
Stock Analyst at Lake Street
(0.84)
# 4,044
Out of 5,182 analysts
30
Total ratings
35.48%
Success rate
-15.43%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chad Messer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGEN Compugen | Initiates: Buy | $6 | $2.92 | +105.48% | 1 | Apr 7, 2026 | |
| IMNM Immunome | Maintains: Buy | $22 → $32 | $23.49 | +36.23% | 2 | Dec 16, 2025 | |
| OSTX OS Therapies | Maintains: Buy | $18 → $17 | $1.77 | +860.45% | 2 | Nov 18, 2025 | |
| GNLX Genelux | Initiates: Buy | $16 | $2.57 | +523.78% | 1 | Oct 21, 2025 | |
| MNPR Monopar Therapeutics | Initiates: Buy | $106 | $54.02 | +96.22% | 1 | Sep 23, 2025 | |
| BOLT Bolt Biotherapeutics | Maintains: Buy | $4 → $75 | $4.96 | +1,412.10% | 2 | Aug 15, 2025 | |
| ONCY Oncolytics Biotech | Initiates: Buy | $7 | $0.97 | +622.62% | 1 | Aug 13, 2025 | |
| COYA Coya Therapeutics | Initiates: Buy | $16 | $4.40 | +263.64% | 1 | Jul 9, 2025 | |
| LTRN Lantern Pharma | Initiates: Buy | $25 | $2.46 | +916.26% | 1 | Apr 2, 2025 | |
| ESPR Esperion Therapeutics | Maintains: Strong Buy | $134 → $114 | $1.91 | +5,868.59% | 3 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $125.68 | -60.22% | 1 | Jul 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $33 → $48 | $61.60 | -22.08% | 2 | Jul 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $33 → $30 | $44.65 | -32.81% | 3 | Jun 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $29 | $7.82 | +270.84% | 2 | May 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $0.28 | +3,468.88% | 1 | Apr 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $95 → $86 | $72.23 | +19.06% | 2 | Mar 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $44 | $16.49 | +166.83% | 2 | Jan 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $182 → $166 | $20.98 | +691.23% | 1 | Jan 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $18 | $1.42 | +1,167.61% | 1 | May 5, 2020 |
Compugen
Apr 7, 2026
Initiates: Buy
Price Target: $6
Current: $2.92
Upside: +105.48%
Immunome
Dec 16, 2025
Maintains: Buy
Price Target: $22 → $32
Current: $23.49
Upside: +36.23%
OS Therapies
Nov 18, 2025
Maintains: Buy
Price Target: $18 → $17
Current: $1.77
Upside: +860.45%
Genelux
Oct 21, 2025
Initiates: Buy
Price Target: $16
Current: $2.57
Upside: +523.78%
Monopar Therapeutics
Sep 23, 2025
Initiates: Buy
Price Target: $106
Current: $54.02
Upside: +96.22%
Bolt Biotherapeutics
Aug 15, 2025
Maintains: Buy
Price Target: $4 → $75
Current: $4.96
Upside: +1,412.10%
Oncolytics Biotech
Aug 13, 2025
Initiates: Buy
Price Target: $7
Current: $0.97
Upside: +622.62%
Coya Therapeutics
Jul 9, 2025
Initiates: Buy
Price Target: $16
Current: $4.40
Upside: +263.64%
Lantern Pharma
Apr 2, 2025
Initiates: Buy
Price Target: $25
Current: $2.46
Upside: +916.26%
Esperion Therapeutics
Aug 3, 2021
Maintains: Strong Buy
Price Target: $134 → $114
Current: $1.91
Upside: +5,868.59%
Jul 27, 2021
Initiates: Buy
Price Target: $50
Current: $125.68
Upside: -60.22%
Jul 19, 2021
Maintains: Buy
Price Target: $33 → $48
Current: $61.60
Upside: -22.08%
Jun 28, 2021
Maintains: Buy
Price Target: $33 → $30
Current: $44.65
Upside: -32.81%
May 14, 2021
Maintains: Buy
Price Target: $31 → $29
Current: $7.82
Upside: +270.84%
Apr 5, 2021
Initiates: Buy
Price Target: $10
Current: $0.28
Upside: +3,468.88%
Mar 23, 2021
Maintains: Buy
Price Target: $95 → $86
Current: $72.23
Upside: +19.06%
Jan 8, 2021
Maintains: Buy
Price Target: $35 → $44
Current: $16.49
Upside: +166.83%
Jan 8, 2021
Maintains: Buy
Price Target: $182 → $166
Current: $20.98
Upside: +691.23%
May 5, 2020
Maintains: Buy
Price Target: $15 → $18
Current: $1.42
Upside: +1,167.61%